{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Diffuse&page=42", "query": { "condition": "Lymphoma, Diffuse", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 1279, "total_pages": 128, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Diffuse&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Diffuse&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:12:38.055Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01643603", "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Hodgkin's Lymphoma", "Myeloid Leukemia", "Multiple Myeloma", "Myelodysplastic Syndrome", "Lymphoid Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2012-05", "completion_date": "2018-10-09", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643603" }, { "nct_id": "NCT02797470", "title": "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Plasmablastic Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Follicular Lymphoma", "Stage III Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2016-06-23", "completion_date": "2036-03", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 4, "location_summary": "La Jolla, California • Sacramento, California • San Francisco, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02797470" }, { "nct_id": "NCT00109824", "title": "Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Mantle Cell Lymphoma" ], "interventions": [ { "name": "decitabine", "type": "DRUG" }, { "name": "valproic acid", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109824" }, { "nct_id": "NCT02763254", "title": "Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Lymphoma, Large B-Cell, Diffuse", "Post-transplant Lymphoproliferative Disorder" ], "interventions": [ { "name": "baltaleucel-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cell Medica Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1, "start_date": "2016-11", "completion_date": "2018-02-17", "has_results": true, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02763254" }, { "nct_id": "NCT02733042", "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2016-05-11", "completion_date": "2022-08-21", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02733042" }, { "nct_id": "NCT03128359", "title": "High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma", "Graft Versus Host Disease", "Hodgkin Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma", "Secondary Myelodysplastic Syndrome" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan Hydrochloride", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "5 Years to 75 Years" }, "enrollment_count": 38, "start_date": "2017-05-30", "completion_date": "2021-09-15", "has_results": true, "last_update_posted_date": "2024-01-09", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128359" }, { "nct_id": "NCT04980222", "title": "A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2022-03-22", "completion_date": "2026-10-15", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 10, "location_summary": "Duarte, California • Stanford, California • Iowa City, Iowa + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04980222" }, { "nct_id": "NCT03797261", "title": "A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Non-Hodgkin's Lymphoma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "AMG 176", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-03-18", "completion_date": "2019-12-30", "has_results": false, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Iowa City, Iowa + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797261" }, { "nct_id": "NCT00398372", "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphomas: Non-Hodgkin", "Lymphomas: Non-Hodgkin Cutaneous Lymphoma", "Lymphomas: Non-Hodgkin Diffuse Large B-Cell", "Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell", "Lymphomas: Non-Hodgkin Mantle Cell", "Lymphomas: Non-Hodgkin Marginal Zone", "Lymphomas: Non-Hodgkin Peripheral T-Cell", "Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Epratuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2000-11", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2011-06-02", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00398372" }, { "nct_id": "NCT01742988", "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Relapsed Lymphoma", "Refractory Lymphoma", "Relapsed and/or Refractory Lymphoma", "Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)", "Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "Double-hit Lymphoma (DHL)", "Triple-hit Lymphoma (THL)", "Double-expressor Lymphoma (DEL)", "High-grade B-cell Lymphoma (HGBL)" ], "interventions": [ { "name": "fimepinostat", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2012-12", "completion_date": "2020-10-09", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-15T11:12:38.055Z", "location_count": 11, "location_summary": "Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01742988" } ] }